Intravacc Highlights Four Integrated Vaccine Development Platforms for CDMO Partners

Intravacc offers four complementary vaccine development platforms: bacterial vaccines, viral vaccines, conjugate vaccines, and E.coli expressed ...

Intravacc Makes Qualified Vero Cell Banks Available to Accelerate Viral Vaccine Development

Qualified Vero Master Cell Bank and Working Cell Bank, originating from WHO banks, are available for purchase, licensing, and use in ...

Lotte Biologics, Asimov unveil next-gen CDO model that cuts DNA-to-GMP timeline to 8.5 months

Lotte Biologics has teamed up with US biotech firm Asimov to unveil a next-generation contract development organization (CDO) ...

WuXi Biologics' 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site ...
GEN

Exogenus Therapeutics Taps Lonza to Develop a GMP-Compliant Process for Lead Exosome-Based Candidate

Exogenus Therapeutics and Lonza agreed to collaborate on the development of Exo-101, Exogenus’ exosome-based lead candidate. The company specializes in the development of therapeutics based on ...
FierceBiotech

Beyond Rigid Platforms: Adaptive Adenoviral Platform De-Risks Development to GMP

An adenoviral process that works for one construct can fail with the next. A harvest step optimized in development can erode yield at scale, and an early analytical method can stall a program at ...
Pharmabiz

Shilpa Biologicals launches PartnerPower, a proprietary platform for real-time visibility on process development

Shilpa Biologicals launches PartnerPower, a proprietary platform for real-time visibility on process development: Our Bureau, Mumbai Tuesday, June 23, 2026, 12:45 Hrs [IST] Shilpa ...
GEN

Consider Cell Therapy GMP Manufacturing Early in Development

Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...